Study of some gut hormones in different gall bladder disorders in diabetics and non-diabetic patients

ABSTRACT

In a trial to explore the aetiopathogensis of gall bladder disorder in diabetics, two hormones [somatostatin and gastrin] with opposed actions on gall bladder [GB] in motility were assessed. Fifty eight subjects were included 36 diabetics [G[1]] [12 with normal GB [G[1A]], 12 with biliary dyskinesia [G[1B]], 12 with gall stone disease [G[1C]] 12 non diabetic with gall stone disease [G[2]], 10 healthy controls [G[3]]. They were subjected to clinical study, routine laboratory investigations, measurement of glycosylated haemoglobin and fasting serum gastrin, plasma somatostatin, sonographic assessment of GB kinetics and morphology, body mass index [BMI] determination. Serum gastrin level was significantly elevated among the studied groups compared to those of controls with the highest value in G[1C]. Plasma somatostatin level was significantly elevated in diabetics insignificantly did so in non-diabetics with gall stone disease Glycosylated haemoglobin was significantly elevated in diabetics [G[1B] > G[1C] > G[1A]]. Diabetics, non diabetics with GB disorders showed a significant reduction in GB ejection fraction. [G[1C] < G[1B] < G[2]] and a significant elevation in BMI[G[1C] = G[1B] > G[2]]. We concluded that the elevated level of the inhibitory hormone somatostatin in diabetics might participate in the pathogenesis of GB disorders. Elevated level of the weak GB contractility stimulant hormone gastrin seemed to be an ineffective compensatory response